Coeptis Therapeutics Holdings Inc. reports corporate-status, capital-structure and biotechnology developments associated with the company that became Z Squared Inc. after a completed merger and name change. News tied to COEP includes shareholder voting matters, governance updates, operating and financial results, and material agreements.
The company’s biotechnology-related updates include clinical or regulatory disclosures and licensing activity involving majority-owned SNAP Biosciences, the SNAP-CAR NK cell therapy platform, and oncology applications using small-molecule adaptor technology. Later corporate updates center on capital structure, security-status changes and formal transaction disclosures.
Z Squared (Nasdaq: ZSQR) announced completion of its business combination with Coeptis Therapeutics and a Nasdaq Global Market listing under ticker ZSQR, effective April 27, 2026 (CUSIP: 98878K108). The closing followed SEC effectiveness of the Form S-4 and Coeptis stockholder approval.
Following the transaction, the combined company has ~51.5 million shares outstanding; former Z Squared Opco stockholders own ~85% and existing public stockholders own ~15%. Coeptis effected a pro rata distribution of its pre-combination biopharmaceutical subsidiary ownership to its record-date stockholders.
Coeptis (Nasdaq: COEP) announced Nasdaq has approved the post-merger listing application for the combined company under ticker ZSQR, subject to customary conditions and closing of the proposed merger with Z Squared Inc.
The approval follows effectiveness of the Form S-4 (File No. 333-288329) and shareholder approval at the January 30, 2026 meeting. The transaction remains subject to any remaining customary closing conditions and is expected to close in Q2 2026.
Coeptis (Nasdaq: COEP) announced that its shareholders approved the previously announced merger with Z Squared Inc.; the shareholder vote occurred on January 30, 2026. In connection with the combination, Z Squared is expected to become a wholly owned subsidiary of Coeptis upon closing. The transaction remains subject to satisfaction of remaining closing conditions. Additional vote details and merger information are available in the company’s Form 8-K filed with the SEC and on the company investor website.
Coeptis Therapeutics (Nasdaq: COEP) announced that its Form S-4 (File No. 333-288329) relating to the proposed merger with Z Squared has been declared effective by the SEC.
The company said it will begin mailing the definitive proxy statement/prospectus to stockholders of record as of January 2, 2026, and will hold an Annual/Special Stockholder Meeting on January 30, 2026. Notice of the meeting will be mailed on or about January 7, 2026.
Coeptis noted it has submitted an application to list the combined company’s common stock on Nasdaq, but approval is not assured; if not approved the combined company would trade on OTC Markets after the Transaction.
Coeptis Therapeutics (NASDAQ: COEP) is demonstrating a successful dual-track business model that combines revenue generation with biotech innovation. The company reported Q2 2025 revenue of $200,681 while advancing its GEAR Cell Therapy Platform for cancer treatment. Their cash position significantly improved from $532,885 at end-2024 to $1,996,726 by June 2025.
The company secured exclusive worldwide rights to the GEAR Cell Therapy Platform from Karolinska Institutet in March 2025 and completed a $10 million Series A preferred stock offering in February 2025, followed by a private placement targeting $2.5-$5 million in July. Operating expenses increased to $4.67 million in Q2 2025 from $2.83 million year-over-year due to restructuring costs.
Coeptis Therapeutics Holdings (NASDAQ:COEP), a next-gen technology and biopharmaceutical company, has announced the extinguishment of its convertible note with YA II PN, Ltd (Yorkville). The note, which was dated January 16, 2025, represented the company's outstanding debt obligations to Yorkville.
CEO David Mehalick emphasized that clearing this debt strengthens the company's capital structure. The company views this debt clearance as strategically important as it plans to expand into cryptocurrency operations.
Coeptis Therapeutics Holdings (NASDAQ:COEP), a next-gen technology and biopharmaceutical company, has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC). The filing relates to the company's previously announced proposed merger with Z Squared Inc.
The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction. The registration statement is currently pending effectiveness and the information contained within remains subject to change.
SNAP Biosciences, a subsidiary of Coeptis Therapeutics Holdings (NASDAQ: COEP), has entered into a licensing agreement with Monarch Therapeutics to enhance their SNAP-CAR NK cell therapy platform in oncology. The agreement provides SNAP Biosciences access to Monarch's small molecule adaptor technology, which enables SNAP-CAR cells to be directed by small molecule-based adaptors.
The integration of Monarch's technology with SNAP-CAR NK cells allows for simultaneous targeting of multiple tumor antigens and real-time activity modulation, addressing challenges like tumor heterogeneity and antigen escape. Under the agreement terms, Monarch will receive an upfront payment, potential development milestone payments, and royalties on net sales.
NUBURU (NYSE: BURU) has filed a $100 million SEC Registration Statement to support its strategic acquisition plans and blue laser technology business relaunch. The company is awaiting Italian government 'Golden Power' approval to acquire a defense and security business hub, which includes a DefenseTech Business and a SaaS Business component.
The acquisitions are expected to generate over $50 million in revenue for 2025, pending U.S. GAAP accounting and closing date. The regulatory assessment under Italy's \"golden power\" review is anticipated to conclude by the end of June. Additionally, NUBURU is implementing a Transformation Plan focusing on AI and robotics adoption through a partnership with COEPTIS' NexGenAI Affiliates Network.
Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced a definitive merger agreement with Z Squared Inc., a Dogecoin mining company. The merger will transform Coeptis into the largest publicly-traded, Dogecoin-focused mining company globally. Under the agreement, Z Squared will become a wholly-owned subsidiary of Coeptis in exchange for 9,000 U.S. based dogecoin mining machines.
The transaction, expected to close in Q3 2025, will involve Coeptis spinning out its biopharmaceutical operations while maintaining its technology operations. Post-merger, the company will be rebranded as Z Squared, Inc. and continue listing on Nasdaq. The combined entity will focus on mining Dogecoin (DOGE), which currently has a market cap exceeding $20B.
The new leadership team will include David Halabu as CEO and Michelle Burke as COO, while current Coeptis CEO Dave Mehalick will exit the Board upon closing. The merger is subject to shareholder approval, regulatory clearances, and continued Nasdaq listing requirements.